Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
Site Search
Showing 1 - 5 of 5 results
News
|
Sept. 29, 2022
|
3 min read
More than 60 teens from across the country — 25 of whom live with cystic fibrosis — participated online and on Capitol Hill in the Foundation’s Teen Advocacy Day to advocate for the CF community.
News
|
June 27, 2022
|
4 min read
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
Press Release
|
June 21, 2022
|
4 min read
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
News
|
Sept. 1, 2022
|
3 min read
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
News
|
Sept. 2, 2022
|
3 min read